STOCKS TELEGRAPH

Author: Muhammad Ali

  • Why Tuniu Corporation (TOUR) stock is green today?

    Why Tuniu Corporation (TOUR) stock is green today?

    Shares of the Tuniu Corporation (TOUR) stock was green in the current market trading session today on January 25, 2022. TOUR stock price saw a push of 1.01% to reach $1.20 a share at the time of this writing. The trading volume on the last check was 296,449, lower than the average trading volume.

    Tuniu Corporation is operating as an online leisure travel company in the People’s Republic of China. The company offers many packaged tours including organized and self-guided tours along with other travel-related services. TOUR stock has a market cap of $146.9 million and a 544,070 average trading volume.

    What’s Happening with TOUR stock?

    There is no press release or any announcement by the company associated with the rise in the per-share price of this stock. No analyst has upgraded or increased the per-share target price of TOUR stock in recent times. It seems that the stock is rising due to some external factors. The sentiment in the social media platforms is positive, pushing this stock in the upward direction. So, what do you need to know now at this moment? Let’s discuss some recent events of this stock.

    Senior Management Share Purchase Plan:

    Tuniu announced on December 27, 2021, that certain management members and employees of the company wish to purchase Tuniu’s American Depository Shares (ADS). The management members include Mr. Donald Dunde Yu, founder, and CEO of the company, Mr. Wei Zhang, Vice president, and Mr. Anqiang Chen, financial controller. These members and certain employees will use personal funds to purchase ADS up to a maximum of US$2 million within the next six months.

    Financial View of TOUR stock:

    In the third quarter of 2021, the company reported a revenue of RMB114.6 million. This represents a decrease of 7.2% year-over-year from the same period of 2020. Tuniu reported RMB74.9 million cost of revenues in the third quarter of 2021, a 28.1% high from the same period of 2020. Gross profit declined by 38.9% to drop at RMB39.7 million. The net loss of the TOUR stock was RMB36.6 million in the last reported quarter, as compared to RMB62.1 million in the same period of the previous year.

    The operating expenses of the company totaled RMB96.4 million in the third quarter of 2021. These include RMB15.6 million R&D expenses, RMB41.7 million-selling, and marketing expenses, and RMB41.2 million G&A expenses. By the end of the third quarter of 2021, the company had RMB1.0 billion in cash, cash equivalents, and short-term investments.

  • IMARA Inc. (IMRA) stock falls today: What’s going on?

    IMARA Inc. (IMRA) stock falls today: What’s going on?

    Shares of the IMARA Inc. (IMRA) were falling in the current market trading session today on January 25, 2022. IMRA stock price saw a downtrend of 3.18% to drop at $1.52 a share at the time of this writing. The stock was also gloomy in the previous trade and went down by 6.55% at closing.

    IMARA Inc., a clinical-stage biopharmaceutical firm mainly working for patients suffering from rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, which is in the Phase 2b clinical trial to treat thalassemia and sickle cell. IMRA stock has a market cap of $41.25 million and 173,541 average trading volume. Let’s understand the current bearish momentum.

    What’s Happening with IMRA stock?

    IMARA Inc today announced the clearance of its new drug application for tovinontrine (IMR-687) by the U.S Food and Drug Administration. The company applied to start clinical development to treat heart failure with preserved ejection fraction (HFpEF). The company is anticipating the Phase 2 trial in the second quarter of the ongoing year. IMARA will evaluate the tovinontrine in patients who are older than 45 years with persistent HFpEF symptoms. Though the news is positive but did not change the sentiment among investors in the stock market. IMARA stock reached an all-time low at $1.52 so far.

    Clinical Update:

    Back on November 22, 2021, the company announced that it has changed the primary endpoint for the Ardent Phase 2b clinical trial of tovinontrine. The company took this step after getting feedback from the U.S Food and Drug Administration. The fetal hemoglobin (HbF) response was the previous primary endpoint for the Ardent trial. FDA after reviewing the Ardent draft recommended annualized rate of vaso-occlusive crises as the primary endpoint, which was previously the key secondary endpoint.

    Financial View of IMRA stock:

    On November 9, 2021, IMARA announced the financial results for the third quarter ended September 30, 2021, according to which

    The company spent $10.4 million in research and development expenses in the third quarter of 2021. These expenses were $9.5 million in the same tenure as the previous year. The general and administrative expenses of the IMRA reached $3.3 million in the last reported quarter. This represents an increase of $0.3 million from the same period of 2020. The company suffered a $13.6 million net loss attributable to common stockholders or $0.55 per share of IMRA stock. By the end of the third quarter, the company had $102.8 million in cash, cash equivalents, and investments.

  • Innate Pharma S.A. (IPHA) stock climbs in the premarket: Here’s Why

    Innate Pharma S.A. (IPHA) stock climbs in the premarket: Here’s Why

    Shares of the Innate Pharma S.A. (IPHA) stock were climbing in the premarket trading session today on January 25, 2022. IPHA stock price saw a push of 4.31% to reach $3.87 a share at the time of this writing. The stock was gloomy in the previous trading session and went down by 9.95% at closing.

    Innate Pharma S.A. is a biotechnology company that is engaged in the development and commercialization of therapies to treat oncology indications. IPHA stock has a market cap of $305.41 million and 74,167 average trading volume. Let’s understand the current momentum of this stock.

    What’s Happening?

    IPHA stock is hot among investors after the recent release of a number of shares and voting rights by the company. The total no of outstanding shares includes 79,542,627 ordinary shares, 6,514 Preferred Shares 2016, and 7,581 Preferred Shares 2017. The company reported a total no of theoretical voting rights of 80,300,467 and exercisable voting rights of 80,281,892 as of January 1, 2022.

    The total no of theoretical voting rights act as a base for the calculation of crossing of the shareholding threshold. The total no of exercisable voting rights is calculated by ignoring the shares held in treasury by the Company, with suspended voting rights.

    Previous News of IPHA stock:

    On January 5, 2022, the company announced the non-dilutive financing of €28.7M from Société Générale and BNP Paribas in the form of two loans. The initial term for these two loans is one year with five years extension option. This financing will help the company in its research and development activities and strengthen its cash position. A positive prospect for the shareholders of IPHA stock!

    Clinical Update:

    Innate Pharma in the mid of December announced that it had dosed the first patient with IPH6101/SAR443579 in a Phase ½ clinical trial. It is the first NKp46/CD16-based NK cell engager in patients suffering from various types of blood cancer. The company is evaluating the pharmacokinetics, pharmacodynamics, and initial clinical activity of IPH6101/SAR443579 in CD123-expressing various hematological malignancies.

    Financial View of the IPHA stock:

    According to the third recent financial results, Innate Pharma generated €10.3 million in the first nine months of 2021. This represents a significant decline as compared to €33.6 million in the third quarter of 2020. The company had €141.8 million in cash, cash equivalents, and financial assets as of September 30, 2021. The financial liabilities of IPHA stock were €16.1 million at the same time.

  • Why Happiness Development Group Limited (HAPP) stock is down today?

    Shares of the Happiness Development Group Limited (HAPP) stock were gloomy in the current market trading session today on January 21, 2022. HAPP stock price saw a decline of 6.68% to drop at $0.48 a share at the time of this writing. The trading volume on the last check was 474,494, lower than the average trading volume. Let’s have a deep look at this stock.

    Happiness Development Group Limited is operating as the research, developer, and manufacturer as well as seller of nutraceutical and dietary supplement products in China. HAPP stock has a market cap of $16.29 million and a 541,820 average trading volume.

    What’s Happening?

    The current bearish momentum of the HAPP stock is the result of the announcement of a $10 million private placement by the company. Happiness Development today announced that it has signed the security purchase agreement with several non-U.S. strategic investors. According to the agreement, the company will sell 12,500,000 Class A ordinary shares at $0.80 per share price. This represents a 45% premium to the market price of its Class A ordinary shares.

    The company is planning to use net proceeds from the offering in the expansion of its eCommerce sales around the globe. The company also intends to add more products to its eCommerce stores. Part of the proceeds is intended to use for the working capital and general corporate purposes.

    Financial Results of HAPP stock

    Company on January 6, 2022, announced financial results for the six months ended September 30, 2021. In this tenure, the company generated $46.88 million in revenues. This represents a whopping increase of $25.01 million or 114.3% from the same tenure of the previous year. The increase is attributable to the start-up of new goods.

    The operating loss in the six months ended September 30, 2021, for the HAPP stock, was $10.53 million. This operating loss was $14.22 million in the same period of the previous year. The performance in the healthcare products segment resulted in this decline.

    Net loss attributable to the shareholders of the HAPP stock was $ 10.05 million in the six months ended September 30, 2021. In the same tenure of the previous year, the company reported $3.19 million net income attributable to the shareholders of HAPP stock.

    Wrap Up

    The announcement of the private placement is the obvious reason for the decline in HAPP stock. In the last six months, this stock has lost approximately 67%.

  • Why is Tonix Pharmaceuticals Holding Corp. (TNXP) stock gloomy today?

    Shares of the Tonix Pharmaceuticals Holding Corp. (TNXP) stock were declining in the current market trading session today on January 21, 2022. TNXP stock price saw a decline of 8.20% to drop at $0.23 a share at the time of this writing. The stock was also gloomy in the previous trading session and went down by 6.49% at closing. Let’s take a closer look at this stock

    Tonix Pharmaceuticals Holding Corp is a healthcare company that is discovering and developing small molecules to prevent human diseases and alleviate suffering. TNXP stock has a market cap of $125.15 million and a 16,509,559 average trading volume.

    What’s Happening?

    TNXP stock has lost the attention of investors in the stock market after rising for a certain time period today. The sentiment about this stock is not positive, causing the decline in the per-share price in the current market.

    The positive fact about the company is that it is developing TNX-1800, which has shown a great immune response against SARS-CoV-2. The rapidly spreading Omicron is making headlines in the whole world despite the rollout of many vaccines. The nature of the Omicron is very much different from the previous mutations of Covid-19. The vaccines in the market are efficient in neutralizing the antibodies but do not generate a robust T-cell response. The company TNX-1800 is based on its horsepox vector platform. Orthopoxviruses show strong innate and adaptive immune responses along with long-lasting T cell immunity.

    Recent news of TNXP stock

    On January 11, 2022, the company announced that it has enrolled the first participant in the dose-finding study for TNX-2100. It is an in vivo skin test that measures the delayed-type hypersensitivity (DTH) to SARS-CoV-2.  The company is measuring functional T cell immunity via DTH. The management thinks that the TNX-2100 skin test has the potential to meet the needs of the rapid, sensitive, and specific test associated with SARS-CoV-2.

    Financial View of TNXP stock

    In the third quarter of 2021, the company spent $13.1 million in research and development expenses. These expenses were $8.8 million in the same tenure of the previous year. The company spent $5.5 million in general and administrative expenses in the third quarter of 2021, higher than the previous year’s G&A expenses. Net loss of the common stockholders of TNXP stock was $18.5 million, or $0.05 per share, basic and diluted in Q3,2021. The company ended the quarter with $183.0 million in cash and cash equivalents.

  • Rockwell Medical, Inc. (RMTI) stock Goes Down in Premarket: Here’s Why

    Shares of the Rockwell Medical, Inc. (RMTI) stock were declining in the premarket trading session today on January 21, 2022. RMTI stock price saw a decline of 7.57% to drop at $0.43 a share at the time of this writing. The stock was also gloomy in the previous trading session today and went down by 8.61% at closing. Let’s deep dive to understand the cause of this decline.

    What’s Happening with RMTI stock?

    RMTI stock is continuing the decline since the previous trading session in the stock market. The sentiment is not positive for this stock even after the announcement of regulatory approval of Triferic® Dialysate in South Korea by the company. Rockwell Medical recently reported that its partner Jeil Pharmaceutical Co., Ltd received the second regulatory approval by the Ministry of Food and Drug Safety of the Republic of Korea for Triferic® Dialysate in South Korea. The product being discussed is intended for maintaining the hemoglobin in adult patients suffering from hemodialysis-dependent chronic kidney disease. Previously on January 13, 2022, Jeil also received the regulatory approval of Triferic® AVNU in South Korea. Now the two products forms of Triferic® have got approval in South Korea.

    Chronic kidney disease is expanding rapidly in South Korea. The global comparative data shows that it is in the 4th position in the world in the prevalence of end-stage kidney disease. Rockwell has the rights under an exclusive license agreement with Jeil to commercialize the Triferic. The company will supply the product to Jeil, as the latter, under the Triferic brand in South Korea, is the exclusive development and commercialization partner.

    Financial View of Rockwell Medical

    According to third-quarter 2021 financial results, the company generated $16.0 million in net sales in the reported quarter. This compares to $15.3 million in the same period of last year. Net sales of the RMTI stock were $15.1 million in the second quarter of 2022. The company reported a $16.3 million cost of sales in the third quarter of 2021 with a $0.3 million gross loss. In the same prior-year period, the company reported a $14.9 million cost of sales and $0.3 million gross profit.

    Rockwell spent $1.2 million in research and development expenses and $1.5 million in selling and marketing expenses in Q3,2021.Net loss of the RMTI stock was $7.5 million, or $0.08 per basic and diluted share. Net loss was $7.4 million in the same quarter of the previous year. By the end of the third quarter, the company had $33.2 million in cash, cash equivalents, and total investments.   

  • Why Digital Brands Group, Inc. (DBGI) stock is rising today?

    Shares of the Digital Brands Group, Inc. (DBGI) stock were rising in the current market trading session today on January 20, 2022. DBGI stock price saw a push of 3.00% to reach $1.37 a share at the time of this writing. The trading volume on the last check was 5,142,431, higher than the average trading volume. Let’s take a closer look to understand the reason behind this bull.

    What’s Happening with DBGI stock?

    DBGI stock has captivated the attention of investors in the current market after the company announced the acquisition of Sundry. Digital Brand Group today announced that it has entered into the definitive merger agreement under which it will acquire Sundry, which is a privately-owned global lifestyle apparel brand. The company expects to complete the transaction in the first of the ongoing year subject to financing and customary closing conditions.

    Highlights of Sundry Acquisition

    • DBGI expects that this acquisition will positively impact the revenues and internal cash flows because of the shared expenses in both marketing and operations.
    • The acquisition will increase brand awareness as well as customer demand. This will help the company in its future growth, a good sign for the shareholders of DBGI stock.
    • Another goal which company expects to achieve through this acquisition is to create significant synergies between all its portfolio. This will result in low customer acquisition costs, customer retention and annual spending per customer as well as higher lifetime value.

    Financial View of DBGI stock

    The company on January 7, 2022, provided a net revenue update for the fourth quarter and fiscal 2021. The company also reaffirmed previously announced 2022 net revenue and EBITDA guidance. Digital Brands expects that its fourth-quarter revenue will come in line with its previously forecasted revenue of approximately $4.0 million. The company reported that the global supply chain disruptions have slightly impacted the revenue.

    The company expects that its revenue for the fiscal year 2021 will increase by 44% to $7.6 million. The previous year’s revenue was $5.2 million for the DBGI stock. The company has not recognized the revenue from Harper & Jones or Stateside for the fiscal year 2021. It is because these brands were acquired during the fiscal year 2021.

    Outlook

    The company reaffirmed the previous guidance of $37.5 million to $42.5 million for the fiscal year 2022. This represents the whooping growth of 350% from the fiscal year 2021 net revenue. In a nutshell, DBGI stock can be a good bet for long-term investors.

  • Evofem Biosciences, Inc. (EVFM) stock declines today: Here’s Why

    Shares of the Evofem Biosciences, Inc. (EVFM) stock were declining in the current market trading session today on January 20, 2022. EVFM stock price saw a decline of 7.59% to drop at $0.45 a share at the time of this writing. The stock was green in the previous trade and went up by 22.86% at closing. Let’s understand the current momentum of this stock.

    What’s Happening with EVFM stock?

    EVFM stock yesterday announced the preliminary results for the fourth quarter of 2021. The strong financial results made the EVFM stock green in the previous trade. The current bearish momentum is the reaction of the previous rise due to the involvement of profit takers. Thus, we can say that this decline is not associated with any negative news related to EVFM stock.

    Evofem Biosciences, Inc develops and commercializes innovative products and product candidates to meet the needs of sexual and reproductive health of women. The stock has a market cap of 79.21 million and a 4,409,219 average trading volume. Let’s take a look at the recent financial results of the Evofem Biosciences.

    Financial View of EVFM stock:

    The company reported strong growth in net product sales of its hormone-free prescription contraceptive gel, Phexxi® in the fourth quarter of 2021. In the reported quarter, the company generated $3.5 million from its net product sales of Phexxi® gel. This represents more than double the net product sales from the third quarter of 2021. The reduced net cash burn rate for the EVFM stock was $17 million in the fourth quarter of 2021. This net cash burn rate was $32.0 million in the third quarter of 2021. The company raised non-dilutive capital of $5 million in January 2022. This will help the company in financing the pivotal Phase 3 trial in STI prevention of Evofem and other ongoing trials.

    Phexxi® Gel Update:

    In the fourth quarter of 2021, the company reported that it has distributed 39,121 boxes of Phexxi gel. This represents a significant increase of 81% from the third quarter of 2021. Filled prescriptions of 32,386 Phexxi increased by 69% from the third quarter of 2021. About 22,659 new patients adopted Phexxi, representing a 56% increase from the third quarter of 2021. These stats represent strong demand for Phexxi, which is a good sign for the growth of the company as well as EVFM stock.

    What’s Next?

    The management is looking forward to taking advantage of guidance issued last week by the Health Resources and Services Administration and the U.S. Department of Labor. In a nutshell, this stock can be a good bet for investors in the long run.

  • Ucommune International Ltd (UK) stock is Popping high in premarket: Here’s Why

    Shares of the Ucommune International Ltd (UK) stock were popping high in the premarket trading session today on January 20, 2022. UK stock price saw a push of 20.53% to reach $0.88 a share at the time of this writing. The stock was gloomy in the previous trading session and went down by 6.40% at closing. Let’s understand the reason behind this rise.

    What’s Happening?

    UK stock has captivated the attention of investors in today’s premarket after experiencing a bearish trend in the last trade. This week is going well for UK stock as it gained nearly 16% in the last five days so far. We can attribute this rise to the recent announcement of a partnership with Nanchang Qinghu Industrial Park Management Company. Under this partnership agreement, Ucommune International will work along with Nanchang Qinghu to jointly develop the Nanchang Honggutan-Ucommune project. The project has a managed area of 56,990 square meters at Nanchang, Jiangxi. The agreement tells that the formal cooperation between both parties started on December 21, 2021, and will end on December 20, 2024.

    Ucommune will take care of all the services related to Honggutan Digital Economy Industrial Park. The smart digital park will provide an industrial ecosystem, online infrastructure, and intelligent operation systems. Moreover, this park will provide premium office spaces to mid-to large-scale digital companies as well as new startups.

    Previous News of UK stock

    On December 28, 2021, the company announced that it has signed a cooperation agreement with Sanhe Metro Land Zhiyuan Real Estate Company Limited, which is a subsidiary of Metro Land Corporate Ltd. Both companies under this agreement will jointly develop the Zhuojun-Ucommune” project in Hebei, China. This project covers the 41,599-square-meter with a managed area of over 10,000-square-meters. The formal cooperation started on January 1, 2022, and will end on June 30, 2023.

    Financial View of the UK stock

    In the third quarter of 2021, Ucommune international reported that it has generated RMB253.5 million in net revenues. This represents a 26.8% increase from the same period of the previous year.Net loss of the UK stock was RMB181.5 million, higher than RMB169.3 million in the same quarter of the previous year. Adjusted net loss in the last reported quarter RMB60.4 million, representing a significant decrease of 49.5% from the same quarter of last year. EBITDA loss of the company was RMB161.2 million and adjusted EBITDA loss was RMB40.4 million in the third quarter of 2021.

  • Why Vaxxinity, Inc. (VAXX) stock is Popping High today?

    Why Vaxxinity, Inc. (VAXX) stock is Popping High today?

    Shares of the Vaxxinity, Inc. (VAXX) stock were popping high in the current market trading session today on January 19, 2022. VAXX stock price saw a surge of 16.44% to reach $8.57 a share at the time of this writing. The trading volume was 1,933,156, far higher than the average trading volume. Let’s understand the reason behind this rally.

    What’s Happening with VAXX stock?

    A few days ago, Vaxxinity announced that it has dosed the first patient with Parkinson’s disease with UB-312 in Part B of a double-blinded, placebo-controlled Phase 1 clinical trial. Previously the company completed part A of the Phase 1 trial in healthy volunteers. This is another milestone of the company in its effort to meet the needs of patients with UB-312. This reflects the positive progress of the company and is a good sign for long-term shareholders of VAXX stock.

    UB-312 is a synthetic peptide vaccine that targets toxic forms aggregated α-synuclein (aSyn). It is the protein essential for synaptic functions. It also regulates the neurotransmitter release at the synapse. aSyn mutation causes the development of Parkinson’s disease and other synucleinopathies which include dementia and multiple system atrophy.

    New Appointment

    In the first week of January, the company announced that it had appointed Jason Pesile, MBA, CPA as the Senior Vice President, Finance & Accounting. The company also appointed George Hornig, Chairman of Xometry, as a member of its board of directors.  Mr. Hornig is now serving the company as the independent director to chair the audit committee.

    Financial View of the VAXX stock

    VAXX on December 24, 2021, did announce the financial results of the third quarter ended September 30, 2021, according to which

    The net loss of the VAXX stock was $30.4 million in the third quarter of 2021. This compares to $16.5 million in the same tenure of the previous year. The company spent $6.7 million in general and administrative expenses in the third quarter of 2021. The expenses were higher as compared to $5.1 million in the third quarter of the same period of the previous year. Research and development expenses in the third quarter of 2021 were $23.6 million, higher than $7.8 million in the prior-year same tenure. By the end of the third quarter, VAXX had $89.4 million in cash and cash equivalents.